TP53 and acute myeloid leukemia: Kaplan–Meier analysis of OS among AML MK TP53 Mut patients and their MK TP53 WT counterparts demonstrated a significant difference in OS (median OS of 5 versus 12.5 months, p < 0.001) (Figure 2D).